Form 4: Oncology Institute's Chief Medical Officer, Yale Podnos, Reports Changes in Beneficial Ownership

Yale Podnos, Chief Medical Officer of Oncology Institute, reports the acquisition and disposal of common stock and RSU awards.

Summary

• On March 31, 2025, Yale Podnos, the Chief Medical Officer of Oncology Institute, Inc., reported changes in beneficial ownership of the company's securities.
• Podnos acquired 157,088 shares of common stock and disposed of 236,137 shares.
• The acquisition of common stock was priced at $0.
• The reported transactions leave Podnos with 236,137 shares of common stock beneficially owned.
• The filing also details RSU awards that vest over four years, subject to continued service with the company.

Sentiment

Score: 5

Explanation: This is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions by a company insider.

Future Outlook

The RSU awards vest over a four-year period, contingent on continued service with the company.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It's important for investors to monitor these filings to understand management's perspective on the company's stock.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company insiders as it can provide insights into management's view of the company's prospects.

Key Dates

Keywords

Oncology Institute, Yale Podnos, beneficial ownership, Form 4, RSU, common stock, Chief Medical Officer